Last10K.com

Eagle Pharmaceuticals, Inc. (EGRX) SEC Filing 10-K Annual report for the fiscal year ending Thursday, December 31, 2015

Eagle Pharmaceuticals, Inc.

CIK: 827871 Ticker: EGRX

Exhibit 99.1

 

 

For Immediate Release

 

Eagle Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2015 Results

 

-Eagle Achieves Full Year 2015 Net Income of $0.16 Per Diluted Share-

 

WOODCLIFF LAKE, N.J.—February 25, 2016—Eagle Pharmaceuticals, Inc. (“Eagle” or “the Company”) (Nasdaq: EGRX) today announced its financial results for the three- and twelve-month periods ended December 31, 2015. Highlights of and subsequent to the fourth quarter of 2015 include:

 

Business Highlights:

 

·                  Received approval from the U.S. Food and Drug Administration (“FDA”) of BENDEKA™, triggering a $15 million milestone payment from Teva Pharmaceutical Industries Ltd.  The Company will receive a 20% royalty on net sales of BENDEKA, which became commercially available as of January 28, 2016, as well as a potential incremental step-up royalty upon the achievement of a future milestone;

·                  Received Fast Track Designation from the FDA for RYANODEX® for the treatment of Exertional Heat Stroke (“EHS”). In September 2015, the Company had reported positive outcomes from Eagle’s safety and efficacy study to evaluate RYANODEX as an EHS treatment;

·                  Announced the commercial availability of Alcohol-Free Docetaxel Injection (“Docetaxel Injection”) in February 2016 following the product’s approval by the FDA in December 2015;

·                  Entered into an agreement with Albany Molecular Research, Inc. (“AMRI”) to jointly develop and manufacture several select and complex parenteral drug products for commercialization in the United States, which is expected to expand Eagle’s portfolio of existing products and product candidates targeting therapeutic areas including oncology, critical care and orphan diseases;

·                  Appointed Sherry Korczynski, a pharmaceutical industry veteran whose 20-plus years of experience include overseeing the marketing of EpiPen®, as Eagle’s Senior Vice President of Marketing. Ms. Korczynski will drive commercial penetration of Eagle’s expanded product portfolio in 2016;

·                  Appointed Michael Moran, a seasoned pharmaceutical sales executive who most recently served as field vice president at GlaxoSmithKline, as U.S. Head of Sales. Mr. Moran will coordinate Eagle’s co-promotional activities with Spectrum Pharmaceuticals while continuing to build the Company’s internal sales force; and

·                  Received sixth Orange Book listed patent for bendamustine hydrochloride formulations further supporting the longevity and long-term earnings potential of the bendamustine franchise products.

 


The following information was filed by Eagle Pharmaceuticals, Inc. (EGRX) on Thursday, February 25, 2016 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Eagle Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Eagle Pharmaceuticals, Inc..

Continue

Assess how Eagle Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Eagle Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2016 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information Document
Balance Sheets
Balance Sheets (parenthetical)
Statements Of Cash Flows
Statements Of Cash Flows (parenthetical)
Statements Of Changes In Stockholders' Equity (deficit)
Statements Of Operations
Arbitration
Arbitration (details)
Asset Sales
Asset Sales (details)
Balance Sheet Accounts
Balance Sheet Accounts (tables)
Balance Sheet Accounts - Accrued Expenses (details)
Balance Sheet Accounts - Deferred Revenue (details)
Balance Sheet Accounts - Prepaid And Other Current Assets (details)
Commitments
Commitments (details)
Commitments (tables)
Commitments - Future Minimum Lease Payments (details)
Common Stock And Stock-based Compensation
Common Stock And Stock-based Compensation (tables)
Common Stock And Stock-based Compensation - Narrative (details)
Common Stock And Stock-based Compensation - Recognized Share-based Compensation (details)
Common Stock And Stock-based Compensation - Share-based Compensation, Options (details)
Income Taxes
Income Taxes (details)
Income Taxes (tables)
Income Taxes - Deferred Income Taxes (details)
Income Taxes - Reconciliation (details)
Inventories
Inventories (details)
Inventories (tables)
Legal Proceedings
Legal Proceedings (details)
License Agreements Of Development And Commercialization Rights
License Agreements Of Development And Commercialization Rights (details)
Notes Payable
Notes Payable (details)
Organization And Business Activities
Organization And Business Activities (details)
Property And Equipment
Property And Equipment (details)
Property And Equipment (tables)
Selected Quarterly Financial Data - Unaudited
Selected Quarterly Financial Data - Unaudited (details)
Selected Quarterly Financial Data - Unaudited (tables)
Shares Subject To Redemption ??? Convertible Preferred Stock
Shares Subject To Redemption ??? Convertible Preferred Stock (details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (policies)
Summary Of Significant Accounting Policies (tables)
Summary Of Significant Accounting Policies - Assumption Of Stock Options Granted (details)
Summary Of Significant Accounting Policies - Common Shares Equivalents Outstanding (details)
Summary Of Significant Accounting Policies - Earnings Per Share (details)
Summary Of Significant Accounting Policies - Major Customers As A Percentage (details)
Summary Of Significant Accounting Policies - Narrative (details)
Transition Period
Transition Period (details)
Transition Period (tables)
Ticker: EGRX
CIK: 827871
Form Type: 10-K Annual Report
Accession Number: 0000827871-16-000049
Submitted to the SEC: Mon Feb 29 2016 5:17:42 PM EST
Accepted by the SEC: Mon Feb 29 2016
Period: Thursday, December 31, 2015
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/egrx/0000827871-16-000049.htm